Takeover Preparedness and the New Hostile M&A Environment
By Eduardo Gallardo and Matthew Walsh (Gibson, Dunn & Crutcher LLP)
The recent financial turmoil has left many public companies' market capitalizations at 10-year lows. Such depressed stock prices and the inability to access traditional sources of financing, coupled with the gradual erosion of antitakeover defenses under the pressure of corporate governance groups, have left many public companies vulnerable to a hostile overtureor an activist investor campaign. At the same time, other companies – particularly in thetechnology and pharmaceutical sectors – are flush with cash and searching for bargainacquisition candidates. In this article, we provide a brief overview of the recent spike in hostiletakeover activity and proliferation of activist campaigns and outline steps that companies shouldtake to better prepare themselves for responding to hostile and dissident situations.Last year saw a sharp uptick in hostile takeover attempts, especially in the large cap(greater than $1 billion) space. According to Thomson Financial, in 2008 there were 17 large-cap hostile takeover attempts of U.S. targets, compared to only five in 2007. Despite thisincrease in unsolicited bids, which included Microsoft's $44.6 billion bid to acquire Yahoo!,Samsung Electronics' $5.9 billion bid for SanDisk. and Cadence Design Systems' $1.6 billion bidfor Mentor Graphics, most of these public offers collapsed before a deal could be reached(notable exceptions include King Pharmaceuticals' $1.4 billion bid for Alpharma and Inbev’s$46.4 billion bid for Anheuser-Busch).The hostile M&A trend has continued into 2009 aided, in part, by the continuing declinein stock prices. In fact, as of the end of February, hostile takeover activity accounted for over38% of 2009 announced public M&A deals in the United States, according to FactSetMergerMetrics. And recently, a number of unsolicited efforts have turned into negotiatedtransactions. Recent examples include: Roche Holding’s $42.5 billion all-cash bid for theremaining 44% of Genentech that it does not already control (which resulted in a $46.8 billionnegotiated transaction between the parties); and Japan's Astellas Pharma's $1.1 billion all-cashoffer for CV Therapeutics (which threw the latter into the arms of white knight Gilead Sciences,who offered $1.4 billion). Hostile acquirors have also not shied away from offering their stock as acquisition currency. Examples include Exelon's $6.2 billion all-stock offer for NRG Energyand CF Industries' $2.8 billion all-stock offer for Terra Industries, which, in an ironic twist, hasled CF Industries to become itself the target of a $3.6 billion unsolicited cash and stock offerfrom Canada's Agrium.Not surprisingly, mid cap companies are not immune to unsolicited bids, which maycome from both strategic and financial players. The past few months have seen an increasingnumber of such situations, including Mill Road Capital's $78 million cash bid for R. G. Barry;
*
Eduardo Gallardo is a corporate partner in the New York office of Gibson, Dunn & Crutcher LLP. His practicefocuses primarily on mergers and acquisitions and corporate governance. Matthew Walsh is a corporate associatein the firm’s New York office. This article was written in March 2009. Contact: egallardo@gibsondunn.com.
Commenting has been disabled.